Stock Analysis on Net
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Thermo Fisher Scientific Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Thermo Fisher Scientific Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term obligations and current maturities of long-term obligations
Accounts payable
Accrued payroll and employee benefits
Contract liabilities
Other accrued expenses
Current liabilities
Deferred income taxes
Other long-term liabilities
Long-term obligations, excluding current maturities
Long-term liabilities
Total liabilities
Redeemable noncontrolling interest
Preferred stock, $100 par value; none issued
Common stock, $1 par value
Capital in excess of par value
Retained earnings
Treasury stock at cost
Accumulated other comprehensive loss
Total Thermo Fisher Scientific Inc. shareholders’ equity
Noncontrolling interests
Total equity
Total liabilities, redeemable noncontrolling interest and equity

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Short-term obligations and current maturities of long-term obligations
The proportion fluctuated over the periods, beginning at 3.81% in 2020, decreasing to 2.67% in 2021, peaking at 5.74% in 2022, then steadily declining to 2.27% by 2024, indicating variability in short-term debt management.
Accounts payable
This item showed minor fluctuations, with values ranging between 2.91% and 3.48% throughout the five-year span, suggesting a relatively stable level of trade payables relative to total funding.
Accrued payroll and employee benefits
A steady decline was observable from 2.77% in 2020 to a low of 1.62% in 2023, followed by an increase to 2.04% in 2024, illustrating some changes in compensation liabilities over time.
Contract liabilities
The ratio increased from 1.84% in 2020 to 2.79% in 2021, remaining elevated and slightly rising through 2024, reflecting potential growth in deferred revenue or advances from customers.
Other accrued expenses
This account remained relatively stable, fluctuating slightly around the 3.1% to 3.45% range, indicating consistency in miscellaneous accrued costs.
Current liabilities
After a decrease from 14.92% in 2020 to 14.12% in 2021, current liabilities rose to 17.51% in 2022 before declining steadily to 13.7% by 2024, signifying changes in short-term obligations relative to total capital.
Deferred income taxes
The portion peaked at 4.03% in 2021, dropped to 2.93% in 2022, and declined further to 1.3% by 2024, indicating a decreasing impact of deferred tax liabilities on the capital structure.
Other long-term liabilities
This metric exhibited a slight downward trend from 4.82% in 2020 to 4.1% in 2024, reflecting a modest reduction in other long-term obligations.
Long-term obligations, excluding current maturities
The percentage increased sharply to 33.99% in 2021 before fluctuating downward to 29.86% in 2024, suggesting a peak in long-term debt burden in 2021 with subsequent gradual reduction.
Long-term liabilities
Long-term liabilities rose from 35.09% in 2020 to a high of 42.8% in 2021, then steadily decreased to 35.26% by 2024, indicating a peak followed by deleveraging efforts.
Total liabilities
The overall liabilities ratio peaked in 2021 at 56.92%, followed by a progressive reduction to 48.96% by 2024, evidencing a strategic shift toward decreasing total leverage.
Redeemable noncontrolling interest
This stake appeared in 2021 at 0.13%, remaining virtually unchanged at 0.12% through 2024, showing minimal significance in capital composition.
Common stock
The share of common stock remained steady between 0.45% and 0.63%, showing no significant issuance or buyback impacting par value.
Capital in excess of par value
This item declined sharply from 22.56% in 2020 to 17% in 2021, then remained stable with a slight increase to 18.46% by 2024, suggesting some equity transactions affecting additional paid-in capital.
Retained earnings
Retained earnings steadily increased from 40.72% in 2020 to 54.56% by 2024, indicating consistent profitability and reinvestment in the company over the period.
Treasury stock at cost
The negative balance expanded from -9.87% in 2020 to -19.76% in 2024, implying increased share repurchases or treasury stock accumulation.
Accumulated other comprehensive loss
This loss showed a decrease in magnitude from -4.07% in 2020 to -2.45% in 2021, fluctuated in subsequent years, ending at -2.77% in 2024, reflecting variability but overall a reduction in other comprehensive losses compared to the initial period.
Total shareholders’ equity
Equity as a percentage of total capital decreased sharply from 49.97% in 2020 to 42.88% in 2021, then gradually increased to 50.95% by 2024, showing recovery and growth in equity base.
Noncontrolling interests
Noncontrolling interests were minimal and slightly fluctuated around zero, with a negative value in 2023 and 2024, indicating negligible impact on total equity.
Total equity
Total equity followed the trend of shareholders’ equity, decreasing in 2021 before steadily increasing to over 50% by 2024, suggesting strengthening of the company’s capital position through equity.
Total liabilities, redeemable noncontrolling interest and equity
This total consistently summed to 100% across all periods, confirming the accounting balance between liabilities, interests, and equity.